Casi pharmaceuticals announces upcoming presentation of clinical results for cid-103 at the 67th american society of hematology (ash) annual meeting

- cid-103 is a potential best-in-class, anti-cd38 monoclonal antibody - phase 1 dose escalation study in immune thrombocytopenia (itp) results and update south san francisco, ca / access newswire / november 3, 2025 / casi pharmaceuticals, inc. (nasdaq:casi), a clinical-stage biopharmaceutical company developing cid-103, a potential best-in-class, clinical stage anti-cd38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases, today announced that data will be presented from its phase 1 open-label study of cid-103 in adult patients with immune thrombocytopenia (itp) at the 67th american society of hematology annual meeting and exposition being held december 6-9, 2025, in orlando, florida. poster presentation details title: a dose-escalation and safety study of cid-103 followed by a randomized, open-label, parallel-arm multi-dose study evaluating the efficacy and tolerability of cid-103 in adults with persistent or chronic immune thrombocytopenia authors: chen yunfei, zeping zhou, hu zhou, ruibin huang, zhenyu yan, jun peng, ming hou, james bussel, alexander zukiwski, junping chen, lei zhang session name: 311.
ASH Ratings Summary
ASH Quant Ranking